Journal
CELL HOST & MICROBE
Volume 24, Issue 6, Pages 761-+Publisher
CELL PRESS
DOI: 10.1016/j.chom.2018.10.007
Keywords
-
Categories
Funding
- Medical Research Council (UK) [U105181010]
- Wellcome Trust Investigator Award
- Wellcome Trust Senior Biomedical Research Fellowship
- European Research Council [339223]
- Medical Research Council
- European Research Council (ERC) [339223] Funding Source: European Research Council (ERC)
- MRC [G0801172, G9721629, MC_U105181010] Funding Source: UKRI
Ask authors/readers for more resources
TRIM5 is a RING domain E3 ubiquitin ligase with potent antiretroviral function. TRIM5 assembles into a hexagonal lattice on retroviral capsids, causing envelopment of the infectious core. Concomitantly, TRIM5 initiates innate immune signaling and orchestrates disassembly of the viral particle, yet how these antiviral responses are regulated by capsid recognition is unclear. We show that hexagonal assembly triggers N-terminal polyubiquitination of TRIM5 that collectively drives antiviral responses. In uninfected cells, N-terminal monoubiquitination triggers nonproductive TRIM5 turnover. Upon TRIM5 assembly on virus, a trivalent RING arrangement allows elongation of N-terminally anchored K63-linked ubiquitin chains (N-K63-Ub). N-K63-Ub drives TRIM5 innate immune stimulation and proteasomal degradation. Inducing ubiquitination before TRIM5 assembly triggers premature degradation and ablates antiviral restriction. Conversely, driving N-K63 ubiquitination after TRIM5 assembly enhances innate immune signaling. Thus, the hexagonal geometry of TRIM5's antiviral lattice converts a capsid-binding protein into a multifunctional antiviral platform.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available